Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a 5-year survival rate of 13.3%. First-line treatment relies on two chemotherapy regimens, FOLFIRINOX (FOLFNX) or gemcitabine plus nab-paclitaxel (GEMPAC). However, direct clinical comparisons between these regimens have yielde...

Descrición completa

Detalles Bibliográficos

Principais autores:	Amirsalar Mansouri, Olivia Hart, Sina Aslanabadi, Conner Hartupee, Dicle Yalcin, Garima Sinha, Chiswili Yves Chabu, Aleksandra Cios, Zetao Cheng, Sudhakar Ammanamanchi, Jovanny Zabaleta, John H. Stewart, John T. West, Mitesh J. Borad, Bolni Marius Nagalo, Jiri Adamec, Omeed Moaven
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2026-03-01
Series:	Cells
Assuntos:	PDAC MIA PaCa2 FOLFIRINOX gemcitabine chemotherapy proteomics
Acceso en liña:	https://www.mdpi.com/2073-4409/15/6/531
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!